UNSPSC 51314310: Chlorpheniramine/dextromethorphan/guaifenesin/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314310 Chlorpheniramine/dextromethorphan/guaifenesin/phenylephrine is a Commodity code that nominally targets a specific cough-and-cold medication combination, but recent state and local solicitations tagged under this code do not reflect purchases of this product. Instead, the tagged opportunities show procurement of naloxone and drug deactivation systems, direct-to-manufacturer prescription program design, and generic multi-source pharmaceuticals and over-the-counter products — none of which align with the code's stated scope. The code shows a significant mismatch between its nominal specification and actual purchasing activity under it in the state and local market.

The most concrete recent opportunity is Seminole County, Florida's IFB 60459723LAS for procurement of 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in March 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities. Given the absence of relevant recent activity aligned with the code's stated pharmaceutical composition, this code does not serve as a reliable indicator for cough-and-cold medication procurement in the state and local market and should be cross-referenced with more descriptive pharmaceutical or OTC product codes to identify actual buying patterns in this category.